Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.47 |
| ▸ | NMBR | P28336 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813730 | 1.00 | SIRT2 (0.47) | SIRT2NMBRSYKHRASMAPT | |
| SCHEMBL6810651 | 0.94 | SIRT2 (0.48) | SIRT2NMBRSYKHRASMAPT | |
| SCHEMBL7712921 | 0.94 | SIRT2 (0.48) | SIRT2NMBRSYKHRASMAPT | |
| SCHEMBL6809813 | 0.92 | HRAS (0.51) | SIRT2NMBRSYKHRAS | |
| SCHEMBL7710727 | 0.92 | HRAS (0.51) | SIRT2NMBRSYKHRAS | |
| SCHEMBL6813616 | 0.85 | SIRT2 (0.49) | SIRT2NMBRHRAS | |
| SCHEMBL6813614 | 0.85 | SIRT2 (0.49) | SIRT2NMBRHRAS | |
| SCHEMBL6812843 | 0.83 | SIRT2 (0.51) | SIRT2NMBRHRAS | |
| SCHEMBL6812845 | 0.83 | SIRT2 (0.51) | SIRT2NMBRHRAS | |
| SCHEMBL6812628 | 0.82 | HRAS (0.53) | SIRT2HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | disclosed |